Clinical trial
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
NCT00106834 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00106834 |
|---|---|
| Title | A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis |
| Official title | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Infliximab |
| Enrollment | 378 |
| Completion | Oct 1, 2004 |
| First posted | Apr 1, 2005 |
| Last update posted | May 19, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: